Skip to main content
COAG
NASDAQ Life Sciences

Access Industries and Len Blavatnik Disclose 10.4% Stake in Hemab Therapeutics Post-IPO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$25
Mkt Cap
$1.168B
52W Low
$23
52W High
$32
52W Position info
8.7% above low
Off High info
22% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

COAG is trading near its 52-week low of $23 (8.7% above the low).

Summary

Access Industries and Len Blavatnik have become a major shareholder in Hemab Therapeutics, acquiring a 10.4% stake, including a $19.8 million direct investment in the company's recent IPO at $18.00 per share.


Key Events · Ownership and Investor Activity · COAG

  • New 10.4% Beneficial Ownership

    AI DEN-MAB LLC and affiliated entities, including Len Blavatnik, reported beneficial ownership of 4,876,344 shares, representing 10.4% of Hemab Therapeutics Holdings, Inc. common stock following the company's IPO on May 4, 2026.

  • Significant IPO Investment

    The reporting group purchased 1,100,000 shares directly in the company's initial public offering at the public offering price of $18.00 per share, totaling $19.8 million. This was part of the IPO completed on May 4, 2026.

  • Lock-Up and Investor Rights Agreements

    The reporting persons are subject to a 180-day lock-up agreement from April 30, 2026, restricting share sales, and hold customary demand and piggyback registration rights exercisable after this period.


Analysis · COAG · Life Sciences

Access Industries, led by Len Blavatnik, has disclosed a significant 10.4% beneficial ownership stake in Hemab Therapeutics Holdings, Inc. following its recent initial public offering. This includes a direct purchase of 1.1 million shares in the IPO at $18.00 per share, demonstrating substantial institutional confidence in the company's prospects shortly after its market debut. This investment, made at a price below the current market value, signals strong conviction from a major investor.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COAG was trading at $25.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $23.00 to $32.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COAG - Latest Insights

COAG
Nov 10, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.81
Real-time Price: $40.86 info
Change: -$1.95 (-5%) info
Market Cap: $1.909B info
COAG
Nov 04, 2026, 9:05 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $43.10
Real-time Price: $40.86 info
Change: -$2.24 (-5%) info
Market Cap: $1.909B info
COAG
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $40.97
Real-time Price: $40.86 info
Change: -$0.110 (-0.27%) info
Market Cap: $1.909B info
COAG
Aug 11, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $51.74
Real-time Price: $40.86 info
Change: -$10.88 (-21%) info
Market Cap: $1.909B info
COAG
Aug 11, 2026, 7:50 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $49.87
Real-time Price: $40.86 info
Change: -$9.01 (-18%) info
Market Cap: $1.909B info